Reardon Andrew bought LGND
December 29, 2023 · Form 4 insider transaction
Reardon Andrew bought 179 shares of Ligand Pharmaceuticals Incorporated at $60.71 per share, a transaction worth $10.9K. The trade was recorded as j and disclosed on an SEC Form 4, filed 6 days after the transaction.
Direction
Acquired (buy-side)
Shares
179
Price
$60.71
Total value
$10.9K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeJ: J
Transaction dateDecember 29, 2023
Filing dateJanuary 4, 2024
Shares owned after15,590
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).